The objective of this multicenter trial is to evaluate the safety, immunogenicity and efficacy of a recombinant herpes simplex virus vaccine in adults. Adult subjects discordant for HSV-2 infection are enrolled and susceptible subjects are randomized to receive 3 doses of a recombinant vaccine or placebo. Follow-up evaluations over 18 months will be conducted and the immunologic response of the subjects compared. Frequency of infection between vaccine recipients and placebo controls will be compared.
Showing the most recent 10 out of 589 publications